Company intelligence / Profile preview

Andromeda Biotech Ltd.

Ownership: Private
Employees: ~1
Development stage: Phase 3

Overview

Andromeda Biotech completed patient recruitment for its confirmatory Phase III clinical trial (DIA-AID 2) for DiaPep277 in Type 1 diabetes. The study included 475 patients across 130 medical centers worldwide. Results were expected at the end of 2014. The treatment showed promise in preserving insulin secretion in earlier trials[5][7][8].

Therapeutic areas: Endocrinology
Modalities: Peptide-based immunotherapy
Industry: Biotech

Drug pipeline

1 asset

DiaPep277

Phase 3

Indications: Type 1 diabetes

Partnerships

Teva Pharmaceutical Industries Ltd. (Andromeda acquired DiaPep277 rights from Teva in 2014)[8]

Beyond the preview

Go deeper on Andromeda Biotech Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Andromeda Biotech Ltd..

Explore the full profile